Protease domain exosites regulate extravascular binding of factor IX(a).

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Factor IX (FIX) is a unique vitamin K-dependent coagulation factor with significant extravascular binding.
• Understanding FIX binding and clearance is crucial for developing effective hemophilia therapies.

Purpose of the Study:

• To investigate the impact of protease domain exosites on the in vivo clearance, tissue distribution, and activity of human Factor IX (FIX).
• To evaluate FIX variants with substitutions in key exosites (antithrombin, heparin, and FIX Padua) in hemophilic mouse models.

Main Methods:

• Hemophilic mice (hemophilia B and A) were used to assess human FIX(a) variants with specific protease domain substitutions.
• Pharmacokinetic modeling was employed to determine FIX(a) clearance rates, tissue content, and in vivo activity.
• In vivo models of bleeding (saphenous vein) and thrombosis (carotid artery occlusion) were utilized.

Main Results:

• FIX wild type (WT) showed poor plasma recovery, biphasic clearance, and heterogeneous tissue binding, primarily in the liver.
• FIX variants with exosite substitutions (K126A/K132A, R150A, R170A) exhibited improved plasma recovery and altered tissue distribution compared to WT.
• Despite potentially reduced coagulant activity, certain FIX variants demonstrated intact or enhanced potency in bleeding and thrombosis models.

Conclusions:

• Protease exosites play a critical role in regulating the in vivo clearance, distribution, and activity of human Factor IX.
• Human FIX(a) exhibits extensive and tissue-specific binding to extravascular sites, influencing its pharmacokinetic profile and therapeutic potential.